Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
ITeos, GSK and TIGIT
UPDATED: iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors
After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from the phase 2 TIGIT trial, revealing a more than 30% difference in confirmed overall response rates between the investigational treatment versus monotherapy.
ESMO: GSK, iTeos bring some optimism back to TIGIT
The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective response rate than Jemperli on its own.
Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target
A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising response rates in patients with a type of lung cancer.
TIGIT drug from iTeos shrinks lung tumors in trial
Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.
GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
Teos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy dostarlimab,
GSK, iTeos Lung Cancer Data Set to Reignite Hope for Drug Class
Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious optimism around a class of immunotherapy drugs that has suffered a series of setbacks.
ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.
BioSpace
3d
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...
The Pharma Letter
3d
ESMO 2024: iTeos shares tumble despite TIGIT:PD-1 doublet promise
Shares in iTeos Therapeutics dropped over 20% despite positive interim data from the GALAXIES Lung-201 Phase II study with ...
5d
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
Teos Therapeutics' belrestotug shows promising response rates in lung cancer trials. Read more to see why I'm bullish on ITOS ...
ENDPOINTS NEWS
6d
GSK, iTeos rejuvenate struggling TIGIT space with positive Phase 2 Jemperli combo data in lung cancer
GSK and iTeos have unveiled positive mid-phase data for their PD-1 plus TIGIT doublet in certain lung cancer patients, ...
Investor's Business Daily on MSN
3d
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback